tirzepatide vision changes Comparative ocular outcomes of versus other anti-obesity medications in people with obesity blindness and tirzepatide A small

All patients were 45 years or older, with an initial BMI of 27 kg/m 2 or greater and established CV disease (prior myocardial infarction, prior stroke, or peripheral arterial disease)

Hinney A, Schmidt A, Nottebom K, et al

Appears to enhance weightloss and glucose effects when combined with GLP1, based on dualagonist data (such as tirzepatide). Glucagon receptor activation Increases energy expenditure and promotes fat oxidation when balanced properly with GLP1 and GIP. May help reduce liver fat and visceral (deep abdominal) fat, which are strongly linked to cardiometabolic risk. By combining these three pathways, retatrutide aims to reduce appetite, improve metabolic control, and increase calorie burning more strongly than current single or dualagonist drugs

Notably, these drugs not only act on the glycemic control, but also show protective effects independently of their anti-diabetic effect (Table 1, Figure 1)

IADVL membership and state medical council registration confirm additional credentialing

FOLLOW US ON INSTAGRAM